Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes

Experimental and Therapeutic Medicine

Volumn 9, Issue 3, 2015, Pages 697-706

  Li, Rui Fang ^a,b   Feng, Ying Qian ^c   Chen, Jun Hui ^a   Ge, Lin Tong ^a   Xiao, Shu Yuan ^b   Zuo, Xue Lan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

^c Department of Endocrinology Weapon Industry 521 Hospital   (China)

Author keywords

Apoptosis; Cell cycle; Cell line; Gene; K562; Naringenin; p21; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; DOXORUBICIN; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN G ANTIBODY; MALONALDEHYDE; MESSENGER RNA; MONOCLONAL ANTIBODY; NARINGENIN; POLYCLONAL ANTIBODY; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DAMAGE; CELL PROLIFERATION ASSAY; CELL ULTRASTRUCTURE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; K562 CELL LINE; LEUKEMIA CELL; LOW DRUG DOSE; MTT ASSAY; NEUTROPHIL; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTECTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING;

EID: 84922023876     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2185     Document Type: Article

References (43)

1. Yang C and Zhang X: Incidence survey of leukemia in China. Chin Med Sci J 6: 65-70, 1991.
2. Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574-577, 1996.
3. Durgo K, Koncar M, Komes D, et al: Cytotoxicity of blended versus single medicinal mushroom extracts on human cancer cell lines: contribution of polyphenol and polysaccharide content. Int J Med Mushrooms 15: 435-448, 2013.
4. Ravishankar D, Rajora AK, Greco F and Osborn HM: Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol 45: 2821-2831, 2013.
5. Ameer B, Weintraub RA, Johnson JV, Yost RA and Rouseff RL: Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60: 34-40, 1996.
6. Galati G, Chan T, Wu B and O'Brien PJ: Glutathione-dependent generation of reactive oxygen species by the peroxidase-catalyzed redox cycling of flavonoids. Chem Res Toxicol 12: 521-525, 1999.
7. Shi Y, Dai J, Liu H, et al: Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-kappaB activity in a murine model of asthma. Can J Physiol Pharmacol 87: 729-735, 2009.
8. Arul D and Subramanian P: Inhibitory effect of naringenin (citrus flavonone) on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Biochem Biophys Res Commun 434: 203-209, 2013.
9. Lv Y, Zhang B, Xing G, Wang F and Hu Z: Protective effect of naringenin against acetaminophen-induced acute liver injury in metallothionein (MT)-null mice. Food Funct 4: 297-302, 2013.
10. Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY and Yin MC: Anti-inflammatory and antifibrotic effects of naringenin in diabetic mice. J Agric Food Chem 60: 514-521, 2012.
11. Andrade JE and Burgess JR: Effect of the citrus flavanone naringenin on oxidative stress in rats. J Agric Food Chem 55: 2142-2148, 2007.
12. Lee S, Lee CH, Moon SS, et al: Naringenin derivatives as anti-atherogenic agents. Bioorg Med Chem Lett 13: 3901-3903, 2003.
13. Totta P, Acconcia F, Leone S, Cardillo I and Marino M: Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life 56: 491-499, 2004.
14. Harmon AW and Patel YM: Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res Treat 85: 103-110, 2004.
15. Gao K, Henning SM, Niu Y, et al: The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem 17: 89-95, 2006.
16. Kanno S, Tomizawa A, Hiura T, et al: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28: 527-530, 2005.
17. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH and van den Berg M: Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci 82: 70-79, 2004.
18. Chen YC, Shen SC and Lin HY: Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem Pharmacol 66: 1139-1150, 2003.
19. Kanno S, Shouji A, Hirata R, Asou K and Ishikawa M: Effects of naringin on cytosine arabinoside (Ara-C)-induced cytotoxicity and apoptosis in P388 cells. Life Sci 75: 353-365, 2004.
20. Lozzio CB and Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975.
21. Gewirtz AM, Burger D, Rado TA, Benz EJ Jr and Hoffman R: Constitutive expression of platelet glycoproteins by the human leukemia cell line K562. Blood 60: 785-789, 1982.
22. Iwabuchi K, Nagaoka I, Someya A and Yamashita T: Type IV collagen-binding proteins of neutrophils: possible involvement of L-selectin in the neutrophil binding to type IV collagen. Blood 87: 365-372, 1996.
23. Dalrymple S, Antony L, Xu Y, et al: Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 65: 9269-9279, 2005.
24. Jeon SM, Kim HK, Kim HJ, et al: Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Translat Res 149: 15-21, 2007.
25. Dieckman LM, Freudenthal BD and Washington MT: PCNA structure and function: insights from structures of PCNA complexes and post-translationally modified PCNA. Subcell Biochem 62: 281-299, 2012.
26. Gehen SC, Vitiello PF, Bambara RA, Keng PC and O'Reilly MA: Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia. Am J Physiol Lung Cell Mol Physiol 292: L716-L724, 2007.
27. Pedraza-Fariña LG: Mechanisms of oncogenic cooperation in cancer initiation and metastasis. Yale J Biol Med 79: 95-103, 2006.
28. Croce CM: Oncogenes and cancer. New Engl J Med 358: 502-511, 2008.
29. Lee EW, Lee MS, Camus S, et al: Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 28: 2100-2113, 2009.
30. Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980-3985, 2005.
31. Insinga A, Cicalese A, Faretta M, et al: DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proc Natl Acad Sci USA 110: 3931-3936, 2013.
32. Panno ML, Giordano F, Mastroianni F, et al: Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. FEBS Lett 580: 2371-2380, 2006.
33. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
34. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD and Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med 3: 1233-1241, 1997.
35. Waldman T, Zhang Y, Dillehay L, et al: Cell-cycle arrest versus cell death in cancer therapy. Nat Med 3: 1034-1036, 1997.
36. Wu Q, Kirschmeier P, Hockenberry T, et al: Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 277: 36329-36337, 2002.
37. Rodriguez R and Meuth M: Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17: 402-412, 2006.
38. Rodriguez RJ, Miranda CL, Stevens JF, Deinzer ML and Buhler DR: Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem Toxicol 39: 437-445, 2001.
39. Lee MK, Bok SH, Jeong TS, et al: Supplementation of naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats. Bioorg Med Chem 10: 2239-2244, 2002.
40. Harrison C: Anticancer drugs: A double strike at kinases. Nature reviews. Drug Discov 9: 270, 2010.
41. van Acker FA, Schouten O, Haenen GR, van der Vijgh WJ and Bast A: Flavonoids can replace alpha-tocopherol as an antioxidant. FEBS Lett 473: 145-148, 2000.
42. Badary OA, Abdel-Maksoud S, Ahmed WA and Owieda GH: Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76: 2125-2135, 2005.
43. Arafa HM, Abd-Ellah MF and Hafez HF: Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats. J Egypt Natl Canc Inst 17: 291-300, 2005.